Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Burkitt Lymphoma 1

Interventions

fludarabine phosphate 24Cyclophosphamide 19Mycophenolic Acid 18Peripheral Blood Stem Cell Transplantation 17Whole-Body Irradiation 16Cyclosporine 12Tacrolimus 11Antilymphocyte Serum 11fludarabine 8Sirolimus 7Filgrastim 7Methotrexate 6Busulfan 6Cyclosporins 5Cord Blood Stem Cell Transplantation 5Therapeutics 4Allopurinol 4Rituximab 3Epoetin Alfa 3Darbepoetin alfa 3sargramostim 2liposomal amphotericin B 2Thiotepa 2Radiotherapy 2Prednisone 2Pharmacogenomic Testing 2Pentetic Acid 2Ondansetron 2Morphine 2Interferon-alpha 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic × Association × Plasma cell × Clear all
NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hematologic Diseases, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡